Patents by Inventor Tongfei Wu

Tongfei Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirobicyclic analogues
    Patent number: 11059850
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jonas Verhoeven, Guido Alfons F. Verniest, Johannes Wilhelmus John F. Thuring, Tongfei Wu, Vineet Pande, Lieven Meerpoel, Dirk Brehmer, Weimei Sun, Scott E. Denmark
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 11040031
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 10954214
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • Substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10898504
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Brian Christopher Shook, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Tongfei Wu, Lieven Meerpoel
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 10888550
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 12, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Didier Jean-Claude Berthelot, Tongfei Wu
  • METHODS OF TREATING CANCER USING PRMT5 INHIBITORS
    Publication number: 20200384006
    Abstract: The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 10, 2020
    Inventors: Hillary Joy Millar Quinn, Kathryn Elizabeth Packman, Nahor Haddish-Berhane, Geert S.J. Mannens, Junguo Zhou, Anthony T. Greway, Dirk Brehmer, Yue Guo, Tongfei Wu, Hong Xie, Josh Lauring
  • NOVEL SPIROBICYCLIC ANALOGUES
    Publication number: 20200369707
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 26, 2020
    Inventors: Jonas VERHOEVEN, Guido Alfons F. VERNIEST, Johannes Wilhelmus John F. THURING, Tongfei WU, Vineet PANDE, Lieven MEERPOEL, Dirk BREHMER, Weimei SUN, Scott E. DENMARK
  • NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200360416
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Application
    Filed: March 20, 2020
    Publication date: November 19, 2020
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200289539
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 17, 2020
    Inventors: Didier Jean-Claude BERTHELOT, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Ronaldus Arnodus Hendrika Joseph GILISSEN, Edward Charles LAWSON, Vineet PANDE, Marcus Cornells Bernardus Catbarina PARADE, Wim Bert Griet SCHEPENS, Brian Christopher SHOOK, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE, Weimei SUN, Tongfei WU, Lieven MEERPOEL
  • 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10653711
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: May 19, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20190381012
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 19, 2019
    Inventors: Tianbao LU, Peter J. CONNOLLY, Maxwell David CUMMINGS, Gaston Stanislas Marcella DIELS, Jan Willem THURING, Ulrike PHILIPPAR, James Patrick EDWARDS, Didier Jean-Claude BERTHELOT, Tongfei WU
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20190381019
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 19, 2019
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20190263833
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 29, 2019
    Inventors: Tongfei WU, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Edward Charles LAWSON, Lieven MEERPOEL, Vineet PANDE, Marcus Cornelis Bernardus Catharina PARADÉ, Wim Bert Griet SCHEPENS, Weimei SUN, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE
  • NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20180243328
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Johannes Wilhelmus John F Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20180170909
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 21, 2018
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu
  • Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
    Patent number: 9522932
    Abstract: The invention is directed to a process for the preparation of substituted threonolactone and substituted threose compounds which are intermediates in the synthesis of phosphonate nucleosides being useful antiviral agents.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: December 20, 2016
    Assignee: K.U. Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
    Patent number: 9249177
    Abstract: The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 2, 2016
    Assignee: K.U. Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION
    Publication number: 20160009750
    Abstract: The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base.
    Type: Application
    Filed: September 28, 2015
    Publication date: January 14, 2016
    Inventors: Piet HERDEWIJN, Christophe PANNECOUQUE, Tongfei WU, Erik DE CLERCQ
  • NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS
    Publication number: 20150094311
    Abstract: The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 2, 2015
    Inventors: HENRICUS JACOBUS MARIA GIJSEN, ADRIANA INGRID VELTER, GREGOR JAMES MACDONALD, FRANCOIS PAUL BISCHOFF, TONGFEI WU, SVEN FRANCISCUS ANNA VAN BRANDT, MICHEL SURKYN, MIRKO ZAJA, SERGE MARIA ALOYSIUS PIETERS, DIDIER JEAN-CLAUDE BERTHELOT, MICHEL ANNA JOZEF DE CLEYN, DANIEL OEHLRICH
  • Substituted triazole and imidazole derivatives as gamma secretase modulators
    Patent number: 8946266
    Abstract: The present invention is concerned with novel substituted triazole and imidazole derivatives of Formula (I) wherein R1, R2, A1, A2, A3, A4, X, and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: February 3, 2015
    Assignees: Janssen Pharmaceuticals, Inc., Cellzome Limited
    Inventors: Tongfei Wu, Henricus Jacobus Maria Gijsen, Frederik Jan Rita Rombouts, François Paul Bischoff, Didier Jean-Claude Berthelot, Daniel Oehlrich, Michel Anna Jozef De Cleyn, Serge Maria Aloysius Pieters, Garrett Berlond Minne, Adriana Ingrid Velter′, Sven Franciscus Anna Van Brandt, Michel Surkyn